Tetra Discovery Partners received the equity funding from Shionogi through a development and commercialisation partnership that could top $160m.
Pharmaceutical company Shionogi has invested $35m in Tetra Discovery Partners, a US-based developer of treatments for memory-impairing diseases and neurological conditions, as part of a development and commercialisation agreement.
Tetra is working on therapies for conditions such as Alzheimer’s disease, depression and brain injury, but the Shinogi deal will involve the companies collaborating on the clinical development and commercialisation of a drug candidate known as BPN14770.
BPN14770 is intended to treat the genetic developmental condition Fragile X syndrome as well…
